ログイン
ランキング
お知らせ
ログイン
文献詳細
総説
文献概要
本総説では，医療行為に伴ってプリオンに感染する医原性クロイツフェルト・ヤコブ病の概要と問題点を説明する。併せて，プリオン以外の感染性蛋白の医原性感染をめぐる，現在の理解と今後の課題についても紹介する。
参考文献
1)Brown P, Brandel JP, Sato T, Nakamura Y, MacKenzie J, et al: Iatrogenic Creutzfeldt-Jakob disease, final assessment. Emerg Infect Dis 18: 901-907, 2012
2)厚生労働行政推進調査事業費補助金 難治性疾患等政策研究事業（難治性疾患政策研究事業）プリオン病のサーベイランスと感染予防に関する調査研究班: 平成30年度総括・分担研究報告書. 2019 http://prion.umin.jp/file/survey_result_H30/H30sougou.pdf（最終閲覧日：2020年2月7日）
3)Nakamura Y, Aso E, Yanagawa H: Relative risk of Creutzfeldt-Jakob disease with cadaveric dura transplantation in Japan. Neurology 53: 218-220,1999
4)Parchi P, Strammiello R, Giese A, Kretzschmar H: Phenotypic variability of sporadic human prion disease and its molecular basis: past, present, and future. Acta Neuropathol 121: 91-112, 2011
5)Bishop MT, Will RG, Manson JC: Defining sporadic Creutzfeldt-Jakob disease strains and their transmission properties. Proc Natl Acad Sci U S A 107: 12005-12010, 2010
6)Moda F, Suardi S, Di Fede G, Indaco A, Limido L, et al: MM2-thalamic Creutzfeldt-Jakob disease: neuropathological, biochemical and transmission studies identify a distinctive prion strain. Brain Pathol 22: 662-669, 2012
7)Takeuchi A, Mohri S, Kai H, Tamaoka A, Kobayashi A, et al: Two distinct prions in fatal familial insomnia and its sporadic form. Brain Commun 1: fcz054, 2019［doi: 10.1093/braincomms/fcz054］
8)Kobayashi A, Iwasaki Y, Otsuka H, Yamada M, Yoshida M, et al: Deciphering the pathogenesis of sporadic Creutzfeldt-Jakob disease with codon 129 M/V and type 2 abnormal prion protein. Acta Neuropathol Commun 1: 74, 2013［doi: 10.1186/2051-5960-1-74］
9)Kobayashi A, Matsuura Y, Iwaki T, Iwasaki Y, Yoshida M, et al: Sporadic Creutzfeldt-Jakob disease MM1+2C and MM1 are identical in transmission properties. Brain Pathol 26: 95-101, 2016
10)Kobayashi A, Asano M, Mohri S, Kitamoto T: Cross-sequence transmission of sporadic Creutzfeldt-Jakob disease creates a new prion strain. J Biol Chem 282: 30022-30028, 2007
11)Yamada M, Noguchi-Shinohara M, Hamaguchi T, Nozaki I, Kitamoto T, et al: Dura mater graft-associated Creutzfeldt-Jakob disease in Japan: clinicopathological and molecular characterization of the two distinct subtypes. Neuropathology 29: 609-618, 2009
12)Kobayashi A, Parchi P, Yamada M, Brown P, Saverioni D, et al: Transmission properties of atypical Creutzfeldt-Jakob disease: a clue to disease etiology? J Virol 89: 3939-3946, 2015
13)Kobayashi A, Kitamoto T, Mizusawa H: Iatrogenic Creutzfeldt-Jakob disease. Handb Clin Neurol 153: 207-218, 2018
14)Kobayashi A, Parchi P, Yamada M, Mohri S, Kitamoto T: Neuropathological and biochemical criteria to identify acquired Creutzfeldt-Jakob disease among presumed sporadic cases. Neuropathology 36: 305-310, 2016
15)Bonda DJ, Manjila S, Mehndiratta P, Khan F, Miller BR, et al: Human prion diseases: surgical lessons learned from iatrogenic prion transmission. Neurosurg Focus 41: E10, 2016［doi: 10.3171/2016.5.FOCUS15126］
16)Ritchie DL, Barria MA, Peden AH, Yull HM, Kirkpatrick J, et al: UK Iatrogenic Creutzfeldt-Jakob disease: investigating human prion transmission across genotypic barriers using human tissue-based and molecular approaches. Acta Neuropathol 133: 579-595, 2017
17)Rudge P, Jaumuktane Z, Adlard P, Bjurstrom N, Caine D, et al: Iatrogenic CJD due to pituitary-derived growth hormone with genetically determined incubation times of up to 40 years. Brain 138: 3386-3399, 2015
18)Swerdlow AJ, Higgins CD, Adlard P, Jones ME, Preece MA: Creutzfeldt-Jakob disease in United Kingdom patients treated with human pituitary growth hormone. Neurology 61: 783-791, 2003
19)Cali I, Miller CJ, Parisi JE, Geschwind MD, Gambetti P, et al: Distinct pathological phenotypes of Creutzfeldt-Jakob disease in recipients of prion-contaminated growth hormone. Acta Neuropathol Commun 3: 37, 2015［doi: 10.1186/s40478-015-0214-2］
20)Llewelyn CA, Hewitt PE, Knight RSG, Amar K, Cousens S, et al: Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet 363: 417-421, 2004
21)Wroe SJ, Pal S, Siddique D, Hyare H, Macfarlane R, et al: Clinical presentation and pre-mortem diagnosis of variant Creutzfeldt-Jakob disease associated with blood transfusion: a case report. Lancet 368: 20161-2067, 2006
22)Hamaguchi T, Noguchi-Shinohara M, Nozaki I, Nakamura Y, Sato T, et al: The risk of iatrogenic Creutzfeldt-Jakob disease through medical and surgical procedures. Neuropathology 29: 625-631, 2009
23)Belay ED, Blase J, Sehulster LM, Maddox RA, Schonberger LB: Management of neurosurgical instruments and patients exposed to Creutzfeldt-Jakob disease. Infect Control Hosp Epidemiol 34: 1272-1280, 2013
24)Alcalde-Cabero E, Almazán-Isla J, Bradel JP, Breithaupt M, Catarino J, et al: Health professionals and risk of sporadic Creutzfeldt-Jakob disease, 1965 to 2010. Euro Surveill 17: pii20144, 2012
25)Kane MD, Lipinski WJ, Callahan MJ, Bian F, Durham RA, et al: Evidence for seeding of β-amyloid by intracerebral infusion of Alzheimer brain extracts in β-amyloid precursor protein-transgenic mice. J Neurosci 20: 3606-3611, 2000
26)Meyer-Luehmann M, Coomaraswamy J, Bolmont T, Kaeser S, Schaefer C, et al: Exogenous induction of cerebral β-amyloidogenesis is governed by agent and host. Science 313: 1781-1784, 2006
27)Clavaguera F, Bolmont T, Crowther RA, Abramowski D, Frank S, et al: Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol 11: 909-913, 2009
28)Luk KC, Kehm V, Carroll J, Zhang B, O'Brien P, et al: Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 338: 949-953, 2012
29)Porta S, Xu Y, Restrepo CR, Kwong LK, Zhang B, et al: Patient-derived frontotemporal lobar degeneration brain extracts induce formation and spreading of TDP-43 pathology in vivo. Nat Commun 9: 4220, 2018［doi: 10.1038/s41467-018-06548-9］
30)Ayers JI, Fromholt S, Koch M, DeBosier A, McMahon B, et al: Experimental transmissibility of mutant SOD1 motor neuron disease. Acta Neuropathol 128: 791-803, 2014
31)Lundmark K, Westermark GT, Nyström S, Murphy CL, Solomon A, et al: Transmissibility of systemic amyloidosis by a prion-like mechanism. Proc Natl Acad Sci U S A 99: 6979-6984, 2002
32)Mukherjee A, Morales-Scheihing D, Salvadores N, Moreno-Gonzalez I, Gonzalez C, et al: Induction of IAPP amyloid deposition and associated diabetic abnormalities by a prion-like mechanism. J Exp Med 214: 2591-2610, 2017
33)Jaunmuktane Z, Mead S, Ellis M, Wadsworth JDF, Nicoll AJ, et al: Evidence for human transmission of amyloid-β pathology and cerebral amyloid angiopathy. Nature 525: 247-250, 2015
34)Kovacs GG, Lutz MI, Ricken G, Ströbel T, Höftberger R, et al: Dura mater is a potential source of Aβ seeds. Acta Neuropathol 131: 911-923, 2016
35)Hamaguchi T, Taniguchi Y, Sakai K, Kitamoto T, Takao M, et al: Significant association of cadaveric dura mater grafting with subpial Aβ deposition and meningeal amyloid angiopathy. Acta Neuropathol 132: 313-315, 2016
36)Ritchie DL, Adlard P, Peden AH, Lowrie S, Le Grice M, et al: Amyloid-β accumulation in the CNS in human growth hormone recipients in the UK. Acta Neuropathol 134: 221-240, 2017
37)Duyckaerts C, Sazdovitch V, Ando K, Seilhean D, Privat N, et al: Neuropathology of iatrogenic Creutzfeldt-Jakob disease and immunoassay of French cadaver-sourced growth hormone batches suggest possible transmission of tauopathy and long incubation periods for the transmission of Abeta pathology. Acta Neuropathol 135: 201-212, 2018
38)Purro SA, Farrow MA, Linehan J, Nazari T, Thomas DX, et al: Transmission of amyloid-β protein pathology from cadaveric pituitary growth hormone. Nature 564: 415-419, 2018
39)Tagoe CE, French D, Gallo G, Buxbaum JN: Amyloidogenesis is neither accelerated nor enhanced by injections of preformed fibrils in mice transgenic for wild-type human transthyretin: the question of infectivity. Amyloid 11: 21-26, 2004
40)Wei L, Kawano H, Fu X, Cui D, Ito S, et al: Deposition of transthyretin amyloid is not accelerated by the same amyloid in vivo. Amyloid 11: 113-120, 2004
41)Stangou AJ, Heaton ND, Hawkins PN: Transmission of systemic transthyretin amyloidosis by means of domino liver transplantation. N Engl J Med 352: 2356, 2005
42)Jaunmuktane Z, Quaegebeur A, Taipa R, Viana-Baptista M, Barbosa R, et al: Evidence of amyloid-β cerebral amyloid angiopathy transmission through neurosurgery. Acta Neuropathol 135: 671-679, 2018
43)厚生労働科学研究費補助金 難治性疾患克服研究事業 プリオン病及び遅発性ウイルス感染症に関する調査研究班: プリオン病感染予防ガイドライン（2008年版） http://prion.umin.jp/guideline/cjd_2008all.pdf（最終閲覧日：2020年2月7日）
44)厚生労働科学研究費補助金 難治性疾患等政策研究事業（難治性疾患政策研究事業）プリオン病及び遅発性ウイルス感染症に関する調査研究班, 厚生労働行政推進調査事業費補助金 難治性疾患等政策研究事業（難治性疾患政策研究事業）プリオン病のサーベイランスと感染予防に関する調査研究班: プリオン病診療ガイドライン2017 http://prion.umin.jp/guideline/guideline_2017.pdf（最終閲覧日：2020年2月7日）
45)Atarashi R, Satoh K, Sano K, Fuse T, Yamaguchi N, et al: Ultrasensitive human prion detection in cerebrospinal fluid by real-time quaking-induced conversion. Nat Med 17: 175-178, 2011
46)厚生労働行政推進調査事業費補助金 難治性疾患等政策研究事業（難治性疾患政策研究事業）プリオン病のサーベイランスと感染予防に関する調査研究班, 日本神経病理学会 プリオン病剖検・病理検査推進委員会: プリオン病の剖検マニュアル第2版 http://prion.umin.jp/download.html（最終閲覧日：2020年2月7日）
47)厚生労働省ホームページ: CJDの剖検に関する補助金の申請について. https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou_iryou/kenkou/cjd/index.html（最終閲覧日：2020年2月7日）
掲載誌情報
